ReviewEndocrine, metabolic & immune disorders drug targets2026
Global Trends in Research of Intestinal Cells and Type 2 Diabetes Mellitus: A Bibliometric and Visualized Analysis from 2004 to 2023.
Review in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Tislelizumab-induced delayed-onset diabetic ketoacidosis and hypothyroidism in esophageal adenocarcinoma.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a systemic metabolic disease, type 2 diabetes has gradually become a disease that seriously threatens human health and quality of life worldwide. Many studies have shown that its pathogenesis and treatment are closely related to intestinal cells. However, the research in this field lacks relevant bibliometric analysis. This study aims to review the knowledge structure and research hot spots on intestinal cells and type 2 diabetes and provide a new direction for its future research through bibliometric methods and visual knowledge maps.
methodsUsing the Web of Science Core Collection (WoSCC) database, we searched the related literature on intestinal cells and type 2 diabetes from 2004 to 2023, and made bibliometric analysis through VOSviewer, CiteSpace, the "Bibliometrix" R package, and Scimago Graphica. Combined with Bradford's Law, Price's Law, Lotka's Law, and Zipf's law, bibliometrics analysis was conducted on publication time, author, country/region, keywords, journals, and references related to publications in this field.
resultsA total of 394 articles were included from 51 countries, led by the United States and China. In the past 20 years, the publication of relevant literature has shown a steady growth trend. These articles are from 2486 authors. Among them, Ti-dong Shan and Tao Yu from China have published the most literature, the University of Toronto is the main research institution, the Journal of Biological Chemistry is the journal with the most common citations, and the most prominently cited article is Sugar absorption in the industry: the role of GLUT2.
conclusionThis study is the first bibliometric analysis that comprehensively summarizes the research trends and hot spots of intestinal cells and type 2 diabetes. This information determines the research hot spots and research frontiers in this field. The hot spots of research are "intestinal epithelial cells", "GLP-1", "SGLT-1", "GLUT2", and "intestinal endocrine cell", while "intestinal epithelial stem cells", "short-chain fatty acid", "bile acid" and "bariatric surgery" may be the focus of future research, which helps clinicians better understand the relationship between intestinal cells and type 2 diabetes, and provides a reference direction for future scholars in this field.
Indexed as
Identifiers
40192044What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.